Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial

S Sivaprasad; P Hykin; A.T. Prevost; J Vasconcelos; A Riddell; J Ramu; C Murphy; J Kelly; Rhiannon Edwards; Seow Tien Yeo; J Bainbridge; D Hopkins; B White-Alao

Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial

S Sivaprasad
, P Hykin
, A.T. Prevost
, J Vasconcelos
, A Riddell
, J Ramu
, C Murphy
, J Kelly
, Rhiannon Edwards
, Seow Tien Yeo
, J Bainbridge
, D Hopkins
, B White-Alao

Research output: Book/Report › Commissioned report

Abstract

NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

Original language	English
Publisher	NIHR
Publication status	Published - Jan 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@book{074bf51aa85d4be9aa6609b00a99aaf8,

title = "Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial",

abstract = "NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report",

author = "S Sivaprasad and P Hykin and A.T. Prevost and J Vasconcelos and A Riddell and J Ramu and C Murphy and J Kelly and Rhiannon Edwards and Yeo, \{Seow Tien\} and J Bainbridge and D Hopkins and B White-Alao",

year = "2018",

month = jan,

language = "English",

publisher = "NIHR",

}

TY - BOOK

T1 - Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY)

T2 - a noninferiority randomised trial

AU - Sivaprasad, S

AU - Hykin, P

AU - Prevost, A.T.

AU - Vasconcelos, J

AU - Riddell, A

AU - Ramu, J

AU - Murphy, C

AU - Kelly, J

AU - Edwards, Rhiannon

AU - Yeo, Seow Tien

AU - Bainbridge, J

AU - Hopkins, D

AU - White-Alao, B

PY - 2018/1

Y1 - 2018/1

N2 - NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

AB - NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

M3 - Commissioned report

BT - Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY)

PB - NIHR

ER -

Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial

Abstract

UN SDGs

Fingerprint

Cite this